

Supporting Information

Synthesis of Tetracyclic Indenopyrazolopyrazolones through Cascade Reactions of Aryl Azomethine Imines with Propargyl Alcohols

Linghua Zhang, Jie Zhao, Yuqin Jiang, Xinying Zhang*, and Xuesen Fan*

Henan Key Laboratory of Organic Functional Molecules and Drug Innovation, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 453007, China

E-mail: xinyingzhang@htu.cn; xuesen.fan@htu.cn

Table of Contents

I	General experimental information	S2
II	Experimental procedures and spectroscopic data	S3-S21
III	Mechanism studies	S22-S26
IV	Copies of NMR spectra of 3a-3hh	S27-S65
V	Copies of NMR spectra of V	S66
VI	X-ray crystal structure and data of 3a	S67-S68
VII	X-ray crystal structure and data of V	S69-S70
VIII	Cell antiproliferative activity assay	S71
IX	Copies of NMR spectra of selected propargyl alcohols	S72- S75
X	References	S76


I. General experimental information

Commercial reagents were used without further purification. 2-Benzylidene-3,3-dimethyl-5-oxopyrazolidin-2-iun-1-ide (**1**)^[1] and propargyl alcohols (**2**)^[2,3] were prepared based on literature procedures. [Ru(*p*-cymene)Cl₂]₂ were from commercial sources. Melting points were recorded with a micro melting point apparatus and uncorrected. The ¹H NMR spectra were recorded at 400 MHz or 600 MHz. The ¹³C NMR spectra were recorded at 100 MHz or 150 MHz. The ¹⁹F NMR spectra were recorded at 376 MHz or 565 MHz. Chemical shifts were expressed in parts per million (δ), and were reported as s (singlet), d (doublet), t (triplet), dd (doublet of doublets), m (multiplet), br s (broad singlet), etc. The coupling constants J were given in Hz. High resolution mass spectra (HRMS) were obtained *via* ESI mode by using a MicrOTOF mass spectrometer. All reactions were monitored by thin layer chromatography (TLC) using silica gel plates (silica gel 60 F254 0.25 mm), and components were visualized by observation under UV light (254 and 365 nm).

II. Experimental procedures and spectroscopic data


1. Typical procedure for the synthesis of 3a and spectroscopic data of 3a-3hh

To a reaction tube equipped with a stir bar were charged with 2-benzylidene-3,3-dimethyl-5-oxopyrazolidin-2-iun-1-ide (**1a**, 60.6 mg, 0.3 mmol), HFIP (2 mL), [Ru(*p*-cymene)Cl₂]₂ (4.6 mg, 0.0075 mmol), AgSbF₆ (10.7 mg, 0.03 mmol) and 2-methyl-4-phenylbut-3-yn-2-ol (**2a**, 48.1 mg, 0.3 mmol). The mixture was stirred at 60 °C for 2 h under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (1:1) as eluent to afford **3a**. **3b-3hh** were obtained in a similar manner.



**3,3,10-Tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one
(3a)**

Eluent: petroleum ether/ethyl acetate (1:1). White solid (89.8 mg, 87%), mp 212.3-213.6 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.48-7.39 (m, 6H), 7.33 (t, *J* = 7.6 Hz, 1H), 7.27-7.23 (m, 2H), 4.70 (s, 1H), 2.78 (d, *J* = 15.6 Hz, 1H), 2.41 (d, *J* = 15.6 Hz, 1H), 1.96 (s, 3H), 1.56 (s, 3H), 1.54 (s, 3H), 1.35 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 162.8, 154.6, 148.6, 139.7, 137.1, 133.5, 128.9, 128.7, 128.6, 128.5, 125.9, 125.3, 121.4, 65.7, 60.3, 58.7, 50.1, 27.7, 27.4, 22.5, 21.1 HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₅N₂O 345.1961; found 345.1960.




3b

3,3,7,10,10-Pentamethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one


(3b)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (90.3 mg, 84%), mp 221.5-222.1 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.48-7.40 (m, 5H), 7.34 (d, J = 8.0 Hz, 1H), 7.06-7.04 (m, 2H), 4.66 (s, 1H), 2.77 (d, J = 15.6 Hz, 1H), 2.40 (d, J = 15.6 Hz, 1H), 2.35 (s, 3H), 1.94 (s, 3H), 1.54 (s, 3H), 1.52 (s, 3H), 1.33 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 162.9, 155.0, 148.9, 138.7, 137.2, 136.9, 133.8, 129.0, 128.8, 128.5, 126.6, 125.1, 122.2, 65.4, 60.3, 58.8, 50.2, 27.8, 27.5, 22.6, 21.7, 21.1. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₂₇N₂O 359.2118; found 359.2106.



7-(*tert*-Butyl)-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3c)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (110.5 mg, 92%), mp 205.5-206.0 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.50-7.38 (m, 6H), 7.29-7.26 (m, 2H), 4.67 (s, 1H), 2.77 (d, J = 15.6 Hz, 1H), 2.40 (d, J = 15.6 Hz, 1H), 1.94 (s, 3H), 1.55 (s, 3H), 1.53 (s, 3H), 1.32 (s, 3H), 1.29 (s, 9H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 162.8, 154.9, 152.2, 148.5, 137.4, 136.8, 133.7, 128.9, 128.7, 128.4, 124.8, 122.8, 118.4, 65.2, 60.2, 58.7, 50.1, 34.9, 31.5, 27.7, 27.4, 22.5, 21.0. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₇H₃₃N₂O 401.2587; found 401.2573.



7-Methoxy-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one


ol-1-one (**3d**)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (87.6 mg, 78%), mp 206.5-207.7 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.47-7.45 (m, 2H), 7.43-7.40 (m, 3H), 7.35 (d, $J = 8.4$ Hz, 1H), 6.79 (d, $J = 2.4$ Hz, 1H), 6.76 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.4$ Hz, 1H), 4.65 (s, 1H), 3.78 (s, 3H), 2.78 (d, $J = 15.6$ Hz, 1H), 2.40 (d, $J = 15.6$ Hz, 1H), 1.94 (s, 3H), 1.54 (s, 3H), 1.52 (s, 3H), 1.33 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 163.0, 160.6, 156.2, 150.4, 137.1, 133.6, 131.9, 129.0, 128.8, 128.6, 126.0, 111.1, 107.7, 65.1, 60.4, 58.8, 55.7, 50.2, 27.8, 27.4, 22.6, 21.2. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_2$ 375.2067; found: 375.2053.




7-Fluoro-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (**3e**)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (84.7 mg, 78%), mp 193.2-194.5 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.49-7.38 (m, 6H), 6.96-6.91 (m, 2H), 4.66 (s, 1H), 2.78 (d, $J = 15.6$ Hz, 1H), 2.41 (d, $J = 15.6$ Hz, 1H), 1.95 (s, 3H), 1.55 (s, 3H), 1.52 (s, 3H), 1.34 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 163.6 (d, $^1J_{\text{C}-\text{F}} = 244.9$ Hz), 162.8, 156.9, 151.0 (d, $^3J_{\text{C}-\text{F}} = 8.7$ Hz), 136.6 (d, $^4J_{\text{C}-\text{F}} = 2.9$ Hz), 135.2 (d, $^4J_{\text{C}-\text{F}} = 2.9$ Hz), 132.9, 128.83, 128.78, 128.7, 126.2 (d, $^3J_{\text{C}-\text{F}} = 9.4$ Hz), 112.4 (d, $^2J_{\text{C}-\text{F}} = 22.4$ Hz), 108.9 (d, $^2J_{\text{C}-\text{F}} = 23.8$ Hz), 65.0, 60.3, 58.7, 50.0, 27.6, 27.4, 22.4, 21.1. ^{19}F NMR (376 MHz, CDCl_3): δ -112.65 (td, $J_1 = 8.3$ Hz, $J_2 = 4.1$ Hz). HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{24}\text{FN}_2\text{O}$ 363.1867; found 363.1857.




7-Chloro-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3f)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (80.5 mg, 71%), mp 199.1-200.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.50-7.42 (m, 3H), 7.41-7.36 (m, 3H), 7.23-7.21 (m, 2H), 4.66 (s, 1H), 2.77 (d, *J* = 15.6 Hz, 1H), 2.41 (d, *J* = 15.6 Hz, 1H), 1.94 (s, 3H), 1.55 (s, 3H), 1.51 (s, 3H), 1.33 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 162.8, 156.5, 150.5, 137.9, 136.4, 134.9, 132.8, 128.9, 128.8, 128.7, 126.1, 125.7, 121.6, 65.1, 60.3, 58.7, 50.0, 27.6, 27.4, 22.5, 21.1. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₄ClN₂O 379.1572; found 379.1561.



7-Bromo-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3g)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (73.4 mg, 58%), mp 189.5-190.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.50-7.43 (m, 3H), 7.40-7.37 (m, 4H), 7.31 (d, *J* = 8.0 Hz, 1H), 4.64 (s, 1H), 2.77 (d, *J* = 15.6 Hz, 1H), 2.40 (d, *J* = 15.6 Hz, 1H), 1.94 (s, 3H), 1.54 (s, 3H), 1.51 (s, 3H), 1.33 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 162.8, 156.4, 150.7, 138.4, 136.4, 132.8, 128.9, 128.8, 128.7, 128.6, 126.5, 124.5, 123.0, 65.2, 60.3, 58.7, 49.9, 27.6, 27.4, 22.5, 21.1. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₄BrN₂O 423.1067; found 423.1060.



Methyl 3,3,10,10-tetramethyl-1-oxo-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]-1-phenylpropanoate (3h)


pyrazole-7-carboxylate (3h)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (57.9 mg, 48%), mp 185.6-186.7 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.97 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.2$ Hz, 1H), 7.90 (d, $J = 1.2$ Hz, 1H), 7.53 (d, $J = 7.8$ Hz, 1H), 7.50-7.48 (m, 2H), 7.46-7.42 (m, 3H), 4.73 (s, 1H), 3.90 (s, 3H), 2.79 (d, $J = 15.6$ Hz, 1H), 2.42 (d, $J = 15.6$ Hz, 1H), 1.96 (s, 3H), 1.57 (s, 3H), 1.54 (s, 3H), 1.35 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 166.9, 162.8, 155.7, 149.1, 144.4, 136.8, 132.9, 130.7, 128.9, 128.80, 128.77, 127.6, 125.1, 122.1, 65.5, 60.4, 58.7, 52.3, 50.0, 27.6, 27.4, 22.5, 21.1. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{25}\text{H}_{27}\text{N}_2\text{O}_3$ 403.2016; found 403.2012.



3,3,6,10,10-Pentamethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3i)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (90.3 mg, 84%), mp 185.6-186.7°C. ^1H NMR (600 MHz, CDCl_3): δ 7.46-7.38 (m, 5H), 7.27 (s, 1H), 7.15-7.14 (m, 2H), 4.67 (s, 1H), 2.78 (d, $J = 15.6$ Hz, 1H), 2.42-2.39 (m, 4H), 1.95 (s, 3H), 1.55 (s, 3H), 1.54 (s, 3H), 1.34 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.8, 153.6, 145.9, 139.9, 137.1, 135.7, 133.7, 129.2, 128.9, 128.6, 128.4, 126.3, 121.0, 65.5, 60.3, 58.6, 50.1, 27.7, 27.5, 22.6, 21.5, 21.0. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}$ 359.2118; found 359.2106.



6-Chloro-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3j)

-1-one (3j)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (86.2 mg, 76%), mp 198.6-200.2 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.48-7.39 (m, 6H), 7.35-7.31 (m, 1H), 7.27-7.22 (m, 2H), 4.70 (s, 1H), 2.78 (d, $J = 15.6$ Hz, 1H), 2.41 (d, $J = 15.6$ Hz, 1H), 1.96 (s, 3H), 1.56 (s, 3H), 1.54 (s, 3H), 1.35 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.8, 156.5, 150.5, 137.9, 136.4, 134.9, 132.8, 128.9, 128.8, 128.7, 126.1, 125.7, 121.6, 65.1, 60.3, 58.7, 50.0, 27.6, 27.4, 22.5, 21.1. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{24}\text{ClN}_2\text{O}$ 379.1572; found 379.1565.



3k

6-Bromo-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3k)


Eluent: petroleum ether/ethyl acetate (1:1). Light yellow solid (98.8 mg, 78%), mp 202.4-204.1 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.57 (d, $J = 1.6$ Hz, 1H), 7.48-7.42 (m, 4H), 7.41-7.38 (m, 2H), 7.12 (d, $J = 8.4$ Hz, 1H), 4.67 (s, 1H), 2.78 (d, $J = 16.0$ Hz, 1H), 2.41 (d, $J = 15.6$ Hz, 1H), 1.94 (s, 3H), 1.55 (s, 3H), 1.53 (s, 3H), 1.33 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 162.9, 155.0, 147.5, 141.6, 136.6, 132.9, 131.7, 128.80, 128.76, 128.6, 122.5, 119.8, 65.4, 60.4, 58.6, 50.0, 27.56, 27.52, 22.5, 21.1. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{24}\text{BrN}_2\text{O}$ 423.1067; found 423.1055.



3l


6-Methoxy-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3l)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (85.3 mg, 76%), mp 191.9-193.2 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.46-7.39 (m, 5H), 7.16 (d, $J = 8.4$ Hz, 1H), 7.05 (d, $J = 2.4$ Hz, 1H), 6.86 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.4$ Hz, 1H), 4.67 (s, 1H), 3.84 (s, 3H), 2.78 (d, $J = 16.2$ Hz, 1H), 2.40 (d, $J = 15.6$ Hz, 1H), 1.94 (s, 3H), 1.54 (s, 6H), 1.33 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 162.8, 158.5, 152.2, 141.42, 141.35, 137.0, 133.7, 128.8, 128.6, 128.4, 121.7, 113.3, 112.7, 65.4, 60.3, 58.6, 55.7, 50.1, 27.7, 27.5, 22.6, 21.0. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_2$ 375.2067 ;found 375.2063.



8-Methoxy-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3m)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (18.0 mg, 16%), mp 175.5-176.1 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.352-7.347 (m, 5H), 7.21 (t, $J = 7.8$ Hz, 1H), 7.09 (d, $J = 7.8$ Hz, 1H), 6.87 (d, $J = 8.4$ Hz, 1H), 4.66 (s, 1H), 3.56 (s, 3H), 2.77 (d, $J = 15.6$ Hz, 1H), 2.40 (d, $J = 15.6$ Hz, 1H), 1.88 (s, 3H), 1.54 (s, 6H), 1.20 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 162.8, 154.9, 153.6, 141.7, 136.9, 135.34, 135.28, 127.7, 127.3, 127.2, 118.2, 112.5, 65.8, 60.3, 58.8, 55.5, 50.2, 27.7, 27.5, 22.54, 21.0. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_2$ 375.2067; found 375.2063.



3,3,5,10,10-Pentamethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3n)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (83.8 mg, 78%), mp 202.4-203.2 °C. ^1H NMR (600

MHz, CDCl₃): δ 7.46-7.40 (m, 5H), 7.24 (t, J = 7.8 Hz, 1H), 7.06 (d, J = 7.8 Hz, 2H), 4.69 (s, 1H), 2.72 (d, J = 15.6 Hz, 1H), 2.56 (s, 3H), 2.37 (d, J = 15.6 Hz, 1H), 1.89 (s, 3H), 1.65 (s, 3H), 1.50 (s, 3H), 1.34 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 163.1, 153.0, 149.2, 138.3, 137.4, 135.2, 133.9, 129.2, 129.1, 128.6, 128.4, 119.1, 64.5, 60.8, 57.3, 51.5, 27.8, 25.7, 22.5, 21.8, 20.0. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₂₇N₂O 359.2118; found 359.2108.




5-Fluoro-3,3,10,10-tetramethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3o)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (71.7 mg, 66%), mp 198.2-198.8 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.48-7.41 (m, 5H), 7.34-7.31 (m, 1H), 7.05 (d, J = 7.8 Hz, 1H), 6.96-6.93 (m, 1H), 4.77 (s, 1H), 2.77 (d, J = 15.6 Hz, 1H), 2.42 (d, J = 16.2 Hz, 1H), 1.95 (s, 3H), 1.58 (s, 3H), 1.50 (s, 3H), 1.35 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 163.0, 159.6 (d, ¹J_{C-F} = 246.3 Hz), 155.1, 151.9 (d, ³J_{C-F} = 5.8 Hz), 136.9 (d, ⁴J_{C-F} = 2.9 Hz), 133.1, 131.3 (d, ³J_{C-F} = 8.0 Hz), 128.8, 128.73, 128.71, 124.4 (d, ²J_{C-F} = 16.6 Hz), 117.5 (d, ⁴J_{C-F} = 2.9 Hz), 113.7 (d, ²J_{C-F} = 22.4 Hz), 63.0, 60.6, 58.2, 50.6, 27.6, 25.7 (d, J_{C(H3)-F} = 8.6 Hz), 22.4, 20.5 (d, J_{C(H3)-F} = 2.1 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -112.29 (dd, J₁ = 10.2 Hz, J₂ = 4.0 Hz,). HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₄FN₂O 363.1867; found 363.1860.




3,10,10-Trimethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3p, isomer 1)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (42.0 mg, 42%), mp 191.8-192.1 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.53 (d, $J = 7.2$ Hz, 1H), 7.47-7.41 (m, 5H), 7.34 (t, $J = 7.2$ Hz, 1H), 7.27-7.24 (m, 2H), 4.35 (s, 1H), 3.56-3.51 (m, 1H), 2.74 (dd, $J_1 = 15.6$ Hz, $J_2 = 7.2$ Hz, 1H), 2.60 (dd, $J_1 = 15.6$ Hz, $J_2 = 13.2$ Hz, 1H), 1.99 (s, 3H), 1.55 (d, $J = 6.0$ Hz, 3H), 1.31 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 163.3, 154.2, 148.6, 139.0, 137.6, 133.4, 128.8, 128.7, 128.6, 126.0, 125.5, 121.3, 75.3, 63.1, 59.1, 44.4, 27.9, 23.0, 18.7. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{23}\text{N}_2\text{O}$ 331.1805; found 331.1801.



3,10,10-Trimethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3p, isomer 2)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (44.2 mg, 45%), mp 196.4-197.5 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.47-7.41 (m, 6H), 7.35 (t, $J = 7.2$ Hz, 1H), 7.29-7.24 (m, 2H), 4.73 (s, 1H), 4.07-4.02 (m, 1H), 3.12 (dd, $J_1 = 16.2$ Hz, $J_2 = 7.8$ Hz, 1H), 2.35 (d, $J = 16.2$ Hz, 1H), 1.95 (s, 3H), 1.52 (d, $J = 7.2$ Hz, 3H), 1.33 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.7, 154.7, 148.4, 139.6, 137.7, 133.6, 128.9, 128.8, 128.7, 128.5, 126.0, 124.2, 121.5, 65.3, 59.0, 53.1, 43.7, 27.5, 22.5, 14.9. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{23}\text{N}_2\text{O}$ 331.1805; found 331.1801.



10,10-Dimethyl-9-phenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3q)


Eluent: petroleum ether/ethyl acetate (1:2). Yellow solid (79.7 mg, 84%), mp 176.9-178.0 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.49-7.41 (m, 6H), 7.37-7.33 (m, 1H), 7.28-7.23 (m, 2H), 4.26 (s, 1H), 3.88 (t, $J = 8.4$ Hz, 1H), 3.23-3.16 (m, 1H), 2.99-2.90 (m, 1H), 2.70 (dd, $J_1 = 15.6$ Hz, $J_2 = 7.8$ Hz, 1H), 2.00 (s, 3H), 1.30 (s, 3H). HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{25}\text{N}_2\text{O}$ 333.1825; found 333.1825.

3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 163.4, 154.3, 148.2, 139.2, 137.9, 133.5, 129.0, 128.7, 128.6, 126.1, 124.4, 121.4, 75.4, 59.6, 53.8, 37.2, 27.7, 23.0. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{21}\text{N}_2\text{O}$ 317.1648; found 317.1647.



**3,3,10,10-Tetramethyl-9-(*p*-tolyl)-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one
(3r)**


Eluent: petroleum ether/ethyl acetate (1:1). White solid (81.7 mg, 76%), mp 203.6-204.7 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.46 (d, $J = 7.6$ Hz, 1H), 7.33-7.35 (m, 3H), 7.28-7.22 (m, 4H), 4.69 (s, 1H), 2.78 (d, $J = 15.6$ Hz, 1H), 2.42-2.38 (m, 4H), 1.95 (s, 3H), 1.56 (s, 3H), 1.54 (s, 3H), 1.36 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3) δ : 162.8, 154.1, 148.7, 139.7, 138.4, 137.1, 130.5, 129.4, 128.8, 128.6, 125.8, 125.3, 121.4, 65.6, 60.3, 58.7, 50.1, 27.7, 27.4, 22.5, 21.4, 21.1. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}$ 359.2118; found 359.2119.



9-(4-Methoxyphenyl)-3,3,10,10-tetramethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3s)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (83.1 mg, 74%), mp 214.8-215.2 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.46 (d, $J = 7.6$ Hz, 1H), 7.37-7.34 (m, 2H), 7.33 (d, $J = 7.2$ Hz, 1H), 7.28-7.22 (m, 2H),

6.99 (d, $J = 8.8$ Hz, 2H), 4.68 (s, 1H), 3.87 (s, 3H), 2.78 (d, $J = 16.0$ Hz, 1H), 2.40 (d, $J = 15.6$ Hz, 1H), 1.95 (s, 3H), 1.56 (s, 3H), 1.53 (s, 3H), 1.37 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.8, 159.8, 153.6, 148.7, 139.7, 136.8, 130.1, 128.6, 125.8, 125.7, 125.3, 121.3, 114.1, 65.5, 60.3, 58.7, 55.3, 50.1, 27.7, 27.4, 22.5, 21.0. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_2$ 375.2067; found: 375.2053.



9-(4-Fluorophenyl)-3,3,10,10-tetramethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazole-1-one (3t)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (93.4 mg, 86%), mp 191.6-192.4 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.47 (d, $J = 7.2$ Hz, 1H), 7.41-7.39 (m, 2H), 7.35-7.33 (m, 1H), 7.27-7.24 (m, 1H), 7.22 (d, $J = 7.2$ Hz, 1H), 7.17-7.15 (m, 2H), 4.69 (s, 1H), 2.78 (d, $J = 15.6$ Hz, 1H), 2.41 (d, $J = 16.2$ Hz, 1H), 1.94 (s, 3H), 1.56 (s, 3H), 1.53 (s, 3H), 1.35 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.9, 162.8 (d, $^1J_{\text{C}-\text{F}} = 246.2$ Hz), 154.9, 148.4, 139.6, 136.1, 130.6 (d, $^3J_{\text{C}-\text{F}} = 7.7$ Hz), 129.5 (d, $^4J_{\text{C}-\text{F}} = 3.3$ Hz), 128.7, 126.0, 125.3, 121.1, 115.8 (d, $^2J_{\text{C}-\text{F}} = 21.9$ Hz), 65.7, 60.3, 58.5, 50.0, 27.7, 27.4, 22.5, 21.0. ^{19}F NMR (565 MHz, CDCl_3): δ -112.58 – -112.63 (m). HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{24}\text{FN}_2\text{O}$ 363.1867; found 363.1858.



9-(4-Chlorophenyl)-3,3,10,10-tetramethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazole-1-one (3u)


1-1-one (3u)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (82.8 mg, 73%), mp 199.4-200.4 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.47-7.39 (m, 6H), 7.32 (t, $J = 7.8$ Hz, 1H), 7.25-7.23 (m, 1H), 4.69 (s, 1H), 2.78 (d, $J = 15.6$ Hz, 1H), 2.41 (d, $J = 15.6$ Hz, 1H), 1.95 (s, 3H), 1.55 (s, 3H), 1.53 (s, 3H), 1.35 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.8, 154.7, 148.6, 139.7, 137.1, 133.5, 128.9, 128.7, 128.6, 128.5, 125.9, 125.3, 121.4, 65.7, 60.3, 58.7, 50.1, 27.7, 27.4, 22.5, 21.1. HRMS (ESI) m/z: [M+H] $^+$ Calcd for $\text{C}_{23}\text{H}_{24}\text{ClN}_2\text{O}$ 379.1572; found 379.1565.




9-(4-Bromophenyl)-3,3,10,10-tetramethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-*one* (3v)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (95.0 mg, 75%), mp 206.5-207.7 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.61-7.59 (m, 2H), 7.47 (d, $J = 7.2$ Hz, 1H), 7.36-7.33 (m, 1H), 7.32-7.29 (m, 2H), 7.27-7.25 (m, 1H), 7.21 (d, $J = 7.2$ Hz, 1H), 4.69 (s, 1H), 2.78 (d, $J = 16.2$ Hz, 1H), 2.41 (d, $J = 15.6$ Hz, 1H), 1.94 (s, 3H), 1.56 (s, 3H), 1.53 (s, 3H), 1.36 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.9, 155.3, 148.1, 139.6, 136.0, 132.4, 132.0, 130.5, 128.7, 126.1, 125.4, 122.6, 121.1, 65.8, 60.3, 58.6, 50.0, 27.7, 27.4, 22.6, 21.1. HRMS (ESI) m/z: [M+H] $^+$ Calcd for $\text{C}_{23}\text{H}_{24}\text{BrN}_2\text{O}$ 423.1067; found 423.1048.




3,3,10,10-Tetramethyl-9-(4-(trifluoromethyl)phenyl)-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3w)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (94.0 mg, 76%), mp 209.6-210.4 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.74 (d, *J* = 7.8 Hz, 2H), 7.56 (d, *J* = 7.8 Hz, 2H), 7.49 (d, *J* = 7.8 Hz, 1H), 7.37-7.34 (m, 1H), 7.28 (td, *J*₁ = 7.8 Hz, *J*₂ = 1.2 Hz, 1H), 7.20 (d, *J* = 7.2 Hz, 1H), 4.73 (s, 1H), 2.79 (d, *J* = 15.6 Hz, 1H), 2.42 (d, *J* = 15.6 Hz, 1H), 1.96 (s, 3H), 1.57 (s, 3H), 1.54 (s, 3H), 1.34 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 162.9, 156.3, 148.0, 139.6, 137.4, 135.8, 130.6 (q, ²J_{C-F} = 32.7 Hz), 129.2, 128.8, 126.2, 125.7 (q, ³J_{C-F} = 3.2 Hz), 125.5, 124.0 (q, ¹J_{C-F} = 270.2 Hz), 121.1, 65.9, 60.3, 58.5, 50.0, 27.6, 27.4, 22.7, 21.1. ¹⁹F NMR (565 MHz, CDCl₃): δ -62.61 (s). HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₂₄F₃N₂O 413.1835; found 413.1823.




3,3,10,10-Tetramethyl-9-(*m*-tolyl)-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3x)

Eluent: petroleum ether/ethyl acetate (1:1). White solid (98.9 mg, 92%), mp 199.5-200.4 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.46 (d, *J* = 7.2 Hz, 1H), 7.35-7.32 (m, 2H), 7.27-7.21 (m, 5H), 4.69 (s, 1H), 2.78 (d, *J* = 15.6 Hz, 1H), 2.42-2.39 (m, 4H), 1.95 (s, 3H), 1.56 (s, 3H), 1.53 (s, 3H), 1.36 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 162.8, 154.4, 148.7, 139.7, 138.3, 137.3, 133.4, 129.4, 129.3, 128.61, 128.56, 126.0, 125.8, 125.3, 121.4, 65.6, 60.3, 58.7, 50.1, 27.7, 27.4, 22.5, 21.5, 21.1. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₂₇N₂O 359.2118; found 359.2106.



9-(3-Chlorophenyl)-3,3,10,10-tetramethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazole-1-one (3y)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (91.9 mg, 81%), mp 203.0-204.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.47 (d, *J* = 8.4 Hz, 1H), 7.42-7.39 (m, 3H), 7.35-7.26 (m, 3H), 7.25-7.22 (m, 1H), 4.70 (s, 1H), 2.78 (d, *J* = 16.0 Hz, 1H), 2.41 (d, *J* = 15.6 Hz, 1H), 1.95 (s, 3H), 1.56 (s, 3H), 1.53 (s, 3H), 1.37 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 162.9, 155.8, 148.1, 139.6, 135.7, 135.4, 134.7, 130.0, 128.80, 128.78, 128.7, 127.1, 126.1, 125.4, 121.2, 65.8, 60.3, 58.6, 50.0, 27.7, 27.4, 22.6, 21.1. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₄ClN₂O 379.1572; found 379.1560.



9-(3-Bromophenyl)-3,3,10,10-tetramethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazole-1-one (3z)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (110.2 mg, 87%), mp 189.8-191.2 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.58 (s, 1H), 7.55 (dt, *J*₁ = 7.2 Hz, *J*₂ = 1.8 Hz, 1H), 7.47 (d, *J* = 7.2 Hz, 1H), 7.36-7.32 (m, 3H), 7.28-7.25 (m, 1H), 7.22 (d, *J* = 7.2 Hz, 1H), 4.69 (s, 1H), 2.78 (d, *J* = 15.6 Hz, 1H), 2.41 (d, *J* = 15.6 Hz, 1H), 1.94 (s, 3H), 1.56 (s, 3H), 1.53 (s, 3H), 1.37 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 162.9, 155.8, 148.1, 139.6, 135.7, 135.6, 131.7, 131.6, 130.3, 128.8, 127.5, 126.1, 125.4, 122.8, 121.1, 65.8, 60.3,

58.6, 50.0, 27.7, 27.4, 22.7, 21.1. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₄BrN₂O 423.1067; found 423.1056.



9-(2-Bromophenyl)-3,3,10,10-tetramethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazole-1-one (3aa)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (110.2 mg, 87%), mp 191.8-192.1 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.70 (dd, J₁ = 7.8 Hz, J₂ = 0.6 Hz, 1H), 7.46 (d, J = 7.2 Hz, 1H), 7.39-7.34 (m, 2H), 7.29-7.26 (m, 2H), 7.23 (td, J₁ = 7.8 Hz, J₂ = 1.2 Hz, 1H), 6.86 (d, J = 7.8 Hz, 1H), 4.78 (s, 1H), 2.80 (d, J = 15.6 Hz, 1H), 2.41 (d, J = 15.0 Hz, 1H), 1.88 (s, 3H), 1.56 (s, 3H), 1.54 (s, 3H), 1.39 (s, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 162.9, 155.5, 149.4, 139.6, 134.62, 134.57, 133.1, 131.0, 129.8, 128.7, 127.3, 125.8, 125.0, 123.5, 120.9, 65.6, 60.6, 58.7, 50.0, 27.4, 25.0, 23.5, 21.1. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₄BrN₂O 423.1067; found 423.1060.



3,3,10,10-Tetramethyl-9-(thiophen-2-yl)-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazole-1-one (3bb)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (57.8 mg, 55%), mp 227.7-228.4 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.48-7.46 (m, 2H), 7.43 (dd, J₁ = 5.2 Hz, J₂ = 1.2 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.28-7.25 (m, 1H), 7.21 (dd, J₁ = 3.6 Hz, J₂ = 1.2 Hz, 1H), 7.16 (dd, J₁ = 5.2 Hz, J₂ = 3.6 Hz, 1H), 4.69 (s,

1H), 2.78 (d, $J = 15.6$ Hz, 1H), 2.42 (d, $J = 15.6$ Hz, 1H), 1.99 (s, 3H), 1.56 (s, 3H), 1.53 (s, 3H), 1.50 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.9, 155.7, 148.0, 139.2, 133.8, 129.7, 128.8, 127.7, 127.6, 126.5, 126.2, 125.3, 121.4, 65.9, 60.1, 58.9, 50.1, 27.7, 27.5, 21.9, 21.0. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{23}\text{N}_2\text{OS}$ 351.1526; found 351.1522.



9-Cyclopentyl-3,3,10,10-tetramethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-o ne (3cc)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (70.6 mg, 70%), mp 185.2-186.5 °C. ^1H NMR (600 MHz, CDCl_3): δ 7.40 (d, $J = 7.2$ Hz, 1H), 7.33 (d, $J = 7.2$ Hz, 1H), 7.29 (t, $J = 7.2$ Hz, 1H), 7.17 (td, $J_1 = 7.2$ Hz, $J_2 = 1.2$ Hz, 1H), 4.48 (s, 1H), 3.22-3.16 (m, 1H), 2.78 (d, $J = 15.6$ Hz, 1H), 2.40 (d, $J = 15.0$ Hz, 1H), 2.02-1.87 (m, 6H), 1.83 (s, 3H), 1.81 (s, 3H), 1.77-1.73 (m, 2H), 1.504 (s, 3H), 1.496 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.9, 153.5, 147.3, 140.1, 137.3, 128.0, 125.0, 124.8, 121.8, 65.5, 60.0, 58.5, 50.3, 38.4, 31.2, 30.2, 27.5, 26.80, 26.76, 26.2, 23.6, 21.0. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{29}\text{N}_2\text{O}$ 337.2274; found 337.2264.



9-Cyclopropyl-3,3,10,10-tetramethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-o ne (3dd)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (80.4 mg, 87%), mp 163.2-164.7 °C. ^1H NMR (400

MHz, CDCl₃): δ 7.46 (d, *J* = 7.6 Hz, 1H), 7.39-7.33 (m, 2H), 7.19 (td, *J*₁ = 7.2 Hz, *J*₂ = 0.8 Hz, 1H), 4.48 (d, *J* = 1.2 Hz, 1H), 2.77 (d, *J* = 15.6 Hz, 1H), 2.40 (d, *J* = 15.6 Hz, 1H), 1.92 (s, 3H), 1.82 (m, 3H), 1.70-1.65 (m, 1H), 1.50 (s, 3H), 1.48 (s, 3H), 1.00-0.93 (m, 2H), 0.76-0.70 (m, 1H), 0.54-0.49 (m, 1H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 162.8, 154.0, 149.5, 139.1, 136.8, 128.6, 125.5, 124.8, 121.0, 65.2, 60.1, 58.4, 50.1, 27.4, 25.5, 23.6, 21.0, 7.3, 5.7, 5.0. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₀H₂₅N₂O 309.1961; found 309.1958.



**9-Butyl-3,3,10-trimethyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one
(3ee)**


Eluent: petroleum ether/ethyl acetate (1:1). Yellow syrup (73.9 mg, 76%). ¹H NMR (400 MHz, CDCl₃): δ 7.39 (d, *J* = 7.2 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.28-7.26 (m, 1H), 7.18 (t, *J* = 7.6 Hz, 1H), 4.51 (s, 1H), 2.78 (d, *J* = 15.6 Hz, 1H), 2.62-2.52 (m, 2H), 2.39 (d, *J* = 15.6 Hz, 1H), 1.83 (s, 6H), 1.64-1.56 (m, 2H), 1.50 (s, 3H), 1.49 (s, 3H) 1.47-1.39 (m, 2H), 0.96 (t, *J* = 7.6 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 162.8, 152.6, 149.2, 139.4, 135.1, 128.4, 125.2, 124.8, 120.1, 65.5, 60.1, 58.4, 50.2, 31.1, 27.4, 26.5, 25.5, 23.0, 22.99, 21.0, 13.9. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₁H₂₉N₂O 325.2274; found 325.2274.



3,3-Dimethyl-9,10-diphenyl-10-propyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3ff)


Eluent: petroleum ether/ethyl acetate (1:1). White solid (71.6 mg, 55%), mp 220.0-211.2 °C. ¹H NMR (600

MHz, CDCl₃): δ 7.84 (d, *J* = 7.8 Hz, 2H), 7.49 (d, *J* = 7.2 Hz, 1H), 7.41-7.25 (m, 11H), 4.81 (s, 1H), 2.80 (d, *J* = 15.6 Hz, 1H), 2.66-2.62 (m, 1H), 2.41 (d, *J* = 15.6 Hz, 1H), 1.70-1.64 (m, 1H), 1.52 (s, 3H), 1.46 (s, 3H), 1.29-1.17 (m, 2H), 0.48 (t, *J* = 6.6 Hz, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 163.4, 150.8, 148.6, 143.1, 140.2, 137.6, 133.1, 128.8, 128.61, 128.56, 128.5, 127.6, 127.3, 125.9, 125.5, 121.6, 67.7, 65.8, 60.3, 50.0, 35.3, 27.5, 20.8, 17.8, 13.3. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₃₀H₃₁N₂O 435.2431; found 435.2428.



3,3-Dimethyl-9,10-diphenyl-2,3,4a,10-tetrahydro-1*H*-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol-1-one (3gg)

Eluent: petroleum ether/ethyl acetate (1:1). Light yellow solid (52.9 mg, 45%), mp 211.0-212.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.59-7.55 (m, 3H), 7.50 (d, *J* = 7.6 Hz, 1H), 7.44-7.40 (m, 3H), 7.37-7.35 (m, 4H), 7.33-7.31 (m, 1H), 7.29-7.27 (m, 2H), 5.38 (s, 1H), 5.00 (s, 1H), 2.77 (d, *J* = 15.6 Hz, 1H), 2.41 (d, *J* = 15.6 Hz, 1H), 1.61 (s, 3H), 1.56 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 163.7, 148.5, 147.2, 141.0, 139.9, 138.6, 132.8, 128.9, 128.8, 128.72, 128.68, 128.62, 128.57, 128.2, 126.2, 125.6, 122.2, 65.9, 60.7, 57.1, 49.7, 27.3, 21.1. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₇H₂₅N₂O 393.1961; found 393.1958.




3',3'-Dimethyl-9'-phenyl-2',3'-dihydro-1'H,4a'H-spiro[cyclohexane-1,10'-indeno[1,2-*c*]pyrazolo[1,2-*a*]pyrazol]-1'-one (3hh)

Eluent: petroleum ether/ethyl acetate (1:1). Yellow solid (92.2 mg, 80%), mp 155.6-156.4 °C. ¹H NMR (600 MHz, CDCl₃): δ 7.46-7.43 (m, 3H), 7.42-7.39 (m, 1H), 7.36-7.35 (m, 2H), 7.26-7.24 (m, 1H), 7.21 (td, *J*₁ =

7.8 Hz, J_1 = 1.2 Hz, 1H), 6.82 (d, J = 7.8 Hz, 1H), 4.72 (s, 1H), 2.83 (d, J = 15.6 Hz, 1H), 2.59 (td, J_1 = 12.6 Hz, J_2 = 3.6 Hz, 1H), 2.41-2.36 (m, 2H), 1.94-1.92 (m, 1H), 1.85-1.79 (m, 2H), 1.55 (s, 3H), 1.53 (s, 3H), 1.49-1.43 (m, 1H), 1.34-1.25 (m, 3H), 0.41-0.35 (m, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3): δ 162.9, 153.6, 150.8, 138.5, 136.9, 135.0, 129.3, 128.64, 128.60, 128.1, 125.7, 124.7, 121.5, 65.9, 63.4, 60.5, 50.3, 35.9, 31.7, 27.3, 24.5, 23.0, 22.1, 21.0. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{26}\text{H}_{29}\text{N}_2\text{O}$ 385.2274; found 385.2268.


2. Gram-scale synthesis of **3a**



To a reaction tube equipped with a stir bar were charged with 2-Benzylidene-3,3-dimethyl-5-oxopyrazolidin-2-ium-1-ide (**1a**, 1.01 g, 5 mmol), HFIP (20 mL), $[\text{Ru}(p\text{-cymene})\text{Cl}_2]_2$ (30.6 mg, 0.125 mmol), AgSbF_6 (178.9 mg, 0.5 mmol), and 2-methyl-4-phenylbut-3-yn-2-ol (**2a**, 0.8 g, 5 mmol). The mixture was stirred at 60°C for 2 h under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (1:1) as eluent to afford **3a** (1.47 g, 85%).

III. Mechanism studies

1. H/D exchange experiment



To a reaction tube equipped with a stir bar were charged with 2-benzylidene-3,3-dimethyl-5-oxopyrazolidin-2-ium-1-ide **1a** (40.4 mg, 0.2 mmol) HFIP (1 mL), CD₃OD (0.16 mL, 4 mmol) [Ru(*p*-cymene)Cl₂]₂ (3.1 mg, 0.005 mmol) and AgSbF₆ (7.16 mg, 0.02 mmol). The mixture was stirred at 60 °C for 30 min under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using ethyl acetate/MeOH (20:1) as eluent to give a mixture of **1a** and **1a-d_n**. Upon analyzing the ¹H NMR spectrum of the mixture as shown in Fig. S1, the deuteration percentage was determined as 30%.





Fig. S1 The ¹H NMR spectrum of the products obtained from the H/D exchange experiment

2. Intermolecular kinetic isotope effect study



To a reaction tube equipped with a stir bar were charged with 2-benzylidene-3,3-dimethyl-5-oxopyrazolidin-2-ium-1-ide (**1a**, 40.4 mg, 0.2 mmol) and 2-(benzylidene-2,3,4,5,6-*d*₅)-3,3-dimethyl-5-oxopyrazolidin-2-ium-1-ide (**1a-d**₅, 41.4 mg, 0.2 mmol), HFIP (1 mL), [Ru(*p*-cymene)Cl₂]₂ (3.1 mg, 0.005 mmol), AgSbF₆ (7.16 mg, 0.02 mmol) and 2-methyl-4-phenylbut-3-yn-2-ol (**2a**, 33.2 mg, 0.2 mmol). The mixture was stirred at 60 °C for 2 h under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (1:1) as eluent to give a mixture of **3a** and **3a-d**₄. Upon analyzing the ¹H NMR spectrum of the mixture as shown in Fig. S2, the ratio of **3a** and **3a-d**₄ was determined as 0.7:0.3. Accordingly, the intermolecular KIE (k_H/k_D) was calculated as about 2.3.






Fig. S2 The ^1H NMR spectrum of the products obtained from the intermolecular KIE experiment

3. Isolation and transformation of intermediate V




To a reaction tube equipped with a stir bar were charged with 2-benzylidene-3,3-dimethyl-5-oxopyrazolidin-2-iun-1-ide **1a** (40.4 mg, 0.2 mmol), DCE (1 mL), $[\text{Ru}(p\text{-cymene})\text{Cl}_2]_2$ (3.1 mg, 0.005 mmol), AgSbF_6 (7.16 mg, 0.02 mmol) and 2-methyl-4-phenylbut-3-yn-2-ol (**2a**, 32.1 mg, 0.3 mmol). The mixture was stirred at 60 °C for 30 min under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (1:2) as eluent to afford **V** (36.2 mg, 50%).




1-(2-(2-Hydroxypropan-2-yl)-3-phenyl-1*H*-inden-1-yl)-5,5-dimethyl pyrazolidin-3-one (V)


Eluent: petroleum ether/ethyl acetate (1:2). White solid (54.3 mg, 50%), mp 165.6-166.4 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.38 (br s, 1H), 7.60 (d, *J* = 6.8 Hz, 1H), 7.47-7.44 (m, 2H), 7.40-7.34 (m, 3H), 7.21-7.14 (m, 2H), 6.60-6.58 (m, 1H), 5.31 (br s, 1H), 5.10 (s, 1H), 2.61 (br s, 1H), 2.11 (d, *J* = 16.8 Hz, 1H), 1.59 (br s, 3H), 1.32 (s, 3H), 1.26 (s, 6H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆): δ 173.4, 149.8, 147.8, 140.9, 138.3, 136.9, 129.5, 128.54, 128.45, 127.7, 125.5, 124.3, 120.2, 71.9, 70.8, 62.8, 44.3, 32.6, 32.2. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₇N₂O₂ 363.2067; found 363.2065.




To a reaction tube equipped with a stir bar were charged with **V** (72.4 mg, 0.2 mmol), HFIP (1 mL), [Ru(*p*-cymene)Cl₂]₂ (3.1 mg, 0.005 mmol) and AgSbF₆ (7.16 mg, 0.02 mmol). The mixture was stirred at 60 °C for 2 h under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (1:1) as eluent to afford **3a** (65.4 mg, 95%).



To a reaction tube equipped with a stir bar were charged with **V** (36.2 mg, 0.1 mmol), HFIP (1 mL), [Ru(*p*-cymene)Cl₂]₂ (1.6 mg, 0.0025 mmol). The mixture was stirred at 60 °C for 2 h under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (1:1) as eluent to afford **3a** (20.7 mg, 60%).




To a reaction tube equipped with a stir bar were charged with **V** (36.2 mg, 0.1 mmol), HFIP (1 mL), AgSbF₆ (3.6 mg, 0.01 mmol). The mixture was stirred at 60 °C for 2 h under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (1:1) as eluent to afford **3a** (25.1 mg, 73%).





To a reaction tube equipped with a stir bar were charged with **V** (36.2 mg, 0.1 mmol), HFIP (1 mL). The mixture was stirred at 60 °C for 16 h under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (1:1) as eluent to afford **3a** (14.1 mg, 41%).

IV. Copies of NMR spectra of 3a-3hh




3a


(CDCl₃, 400M)





3a

(CDCl₃, 100M)








(CDCl₃, 400M)







3b
(CDCl₃, 100M)






















































3o
(CDCl₃, 565M)



























(CDCl₃, 565M)








































3dd
(CDCl₃, 150M)









3ee
(CDCl₃, 400M)





3ee
(CD₃Cl, 100M)










(CDCl₃, 400M)





(CDCl₃, 100M)







3hh
(CDCl₃, 600M)



3hh
(CDCl₃, 150M)



V. Copies of the NMR spectra of V



VI. X-ray crystal structure and data of **3a**




Fig. S3 X-ray crystal structure of **3a** with 50% ellipsoid probability

X-ray structure determination. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from a dichloromethane/ethyl acetate (2:1) solution of **3a**. Crystal data collection and refinement parameters of **3a** are summarized in Table S1. Intensity data were collected at 296 K on a SuperNova Dual diffractometer using mirror-monochromated Cu K α radiation, $\lambda = 1.54184 \text{ \AA}$. The data were corrected for decay, Lorentz, and polarization effects as well as absorption and beam corrections based on the multi-scan technique. The structure was solved by a combination of direct methods in SHELXS and the difference Fourier technique, and refined by full-matrix least-squares procedures. Nonhydrogen atoms were refined with anisotropic displacement parameters. The H-atoms were either located or calculated and subsequently treated with a riding model.

Table S1 Crystallographic data and structure refinement results of **3a**

Empirical formula	C ₂₃ H ₂₄ N ₂ O
Formula weight	344.44
Temp, K	296.2 (4)
Crystal system	monoclinic
Space group	P2 ₁ /c
<i>a</i> , Å	15.2849(6)
<i>b</i> , Å	7.3266(3)
<i>c</i> , Å	18.6240(8)
α (°)	90

β (°)	110.556(5)
γ (°)	90
Volume, Å ³	1952.84(15)
Z	4
d_{calc} , g cm ⁻³	1.172
λ , Å	1.54184
μ , mm ⁻¹	0.560
No. of data collected	8198
No. of unique data	3702
R_{int}	0.0282
Goodness-of-fit on F^2	1.086
R_1 , wR ₂ ($I > 2\sigma(I)$)	0.0519, 0.1303
R_1 , wR ₂ (all data)	0.0652, 0.1408

VII. X-ray crystal structure and data of V




Fig. S4 X-ray crystal structure of **V** with H_2O with 50% ellipsoid probability

X-ray structure determination. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from an ethyl acetate solution of **V**. Crystal data collection and refinement parameters of **V** are summarized in Table S2. Intensity data were collected at 295 K on a SuperNova Dual diffractometer using mirror-monochromated Cu $\text{K}\alpha$ radiation, $\lambda = 1.54184 \text{ \AA}$. The data were corrected for decay, Lorentz, and polarization effects as well as absorption and beam corrections based on the multi-scan technique. The structure was solved by a combination of direct methods in SHELXS and the difference Fourier technique, and refined by full-matrix least-squares procedures. Nonhydrogen atoms were refined with anisotropic displacement parameters. The H-atoms were either located or calculated and subsequently treated with a riding model.

Table S2 Crystallographic data and structure refinement results of **V** with H_2O

Empirical formula	$\text{C}_{23}\text{H}_{28}\text{N}_2\text{O}_3$
Formula weight	380.47
Temp, K	294.98(11)
Crystal system	monoclinic
Space group	$\text{P}2_1/\text{c}$
$a, \text{\AA}$	7.0249(3)
$b, \text{\AA}$	24.9828(10)
$c, \text{\AA}$	12.0067(5)

α (°)	90
β (°)	91.724(4)
γ (°)	90
Volume, Å ³	2106.24(15)
Z	4
d_{calc} , g cm ⁻³	1.200
λ , Å	1.54184
μ , mm ⁻¹	0.635
No. of data collected	9870
No. of unique data	4019
R_{int}	0.0352
Goodness-of-fit on F^2	1.220
R_1 , wR ₂ ($I > 2\sigma(I)$)	0.0785, 0.2362
R_1 , wR ₂ (all data)	0.0958, 0.2420


VIII. Cell antiproliferative activity assay



Cell antiproliferative activity was evaluated by the CellTiter-Glo (Promega, USA) assay. Make 1000× compounds solution in DMSO, Add 1 μ l 1000× compounds to 49 μ l growth medium to make 20× compounds. Dilute cell suspensions in growth medium to desired density and 95 μ l were taken to 96-well plate. Add 5 μ l 20× compounds into 96-well plate according to the plate map. Final DMSO concentration in each well was 0.1%. Then the cell was incubated at 37 °C, 5% CO₂ for 72 h. Equilibrate the assay plate to room temperature before measurement. Add 20 μ l of CellTiter-Glo® Reagent into each well. Mix contents for 2 minutes on an orbital shaker to induce cell lysis. Incubate at room temperature for 10 minutes to stabilize luminescent signal. Record luminescence using EnVision Multilabel Reader (PerkinElmer). Cell viability (CV%) was calculated relative to vehicle (DMSO) treated control wells using following formula:




$$\text{Cell viability}(\%) = (\text{RLU compound} - \text{RLU blank}) / (\text{RLU control} - \text{RLU blank}) * 100\%.$$

The IC₅₀ values were calculated using GraphPad Prism 6.0 software, fitting to a 4-parameter equation to generate concentration response curves. All assays were conducted with three parallel samples and three repetitions, and 5-fluorouracil (5-FU) was used as the positive control.



IX. Copies of NMR spectra of selected propargyl alcohols









(CDCl₃, 600M)




31.400



(CDCl₃, 150M)





X. References

- (1) M. Zhang, F. F. Wu, H. H. Wang, J. S. Wu, and W. Z. Chen, *Adv. Synth. Catal.* 2017, **359**, 2768.
- (2) P. K. R. Panyam, and T. Gandhi, *Adv. Synth. Catal.* 2017, **359**, 1144.
- (3) K.W. Feng, Y. L. Ban, P. F. Yuan, W. L. Lei, Q. Liu, and R. Fang, *Org. Lett.* 2019, **21**, 3131.